Comparative Pharmacology
Head-to-head clinical analysis: ECONOCHLOR versus VASOCIDIN.
Peer-Reviewed Evidence
Head-to-head clinical analysis: ECONOCHLOR versus VASOCIDIN.
ECONOCHLOR vs VASOCIDIN
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Econazole nitrate inhibits fungal cytochrome P450 14α-demethylase, blocking ergosterol synthesis, disrupting fungal cell membrane integrity and function.
Vasocidin is a combination of sulfacetamide sodium, a sulfonamide antibiotic that inhibits bacterial dihydropteroate synthase, thereby blocking folate synthesis and bacterial growth, and prednisolone sodium phosphate, a corticosteroid that suppresses inflammation by inhibiting phospholipase A2 and subsequent prostaglandin and leukotriene synthesis.
0.12 mg/kg IV bolus over 30 seconds, followed by continuous IV infusion at 0.12-0.6 mg/kg/h.
One drop of the ophthalmic suspension into the conjunctival sac of the affected eye(s) every 4 hours while awake and at bedtime for 7 days; duration may be extended based on clinical response.
None Documented
None Documented
Terminal half-life: 8-10 hours in adults with normal renal function; prolonged to 15-20 hours in renal impairment (CrCl <30 mL/min).
Terminal elimination half-life is 6-8 hours in patients with normal renal function; prolonged in renal impairment.
Renal: 80-90% as unchanged drug; fecal: <1%; biliary: minimal.
Renal: 70-80% as unchanged drug; biliary/fecal: 20-30% as metabolites and unchanged drug.
Category C
Category C
Ophthalmic Antibiotic
Ophthalmic Antibiotic/Corticosteroid Combination